One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Ardelyx logo
Ardelyx ARDX
$ 3.0 2.04%
report update icon

Quarterly report 2026-Q3
added 11-03-2026

Ardelyx Balance Sheet 2025-2011 | ARDX

Brief overview of Ardelyx's assets and capital

The balance sheet is assessed across five available annual reports spanning 2021 to 2025.

The asset base grew from $149.9 million to $501.6 million, or +234.6%. Average annual growth of roughly 35.2% was strong.

Liabilities expanded faster than the asset base, +397.3% versus +234.6%. Debt-service capacity deserves attention.

Equity represents 33.3% of assets versus 55.1% initially. The capital structure appears balanced.

Net debt reached $136.3 million, equal to 0.82x of equity. The debt profile is moderately stretched.

The cash share moved from 48.3% to 13.6%. A higher figure generally provides more room in an adverse scenario.

The balance sheet includes a negative accumulated result of -$946.9 million. It should be assessed alongside historical profits and capital distributions.

Overall picture

Ardelyx's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.

Annual Balance Sheet Ardelyx

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

136 M 87.5 M 32.8 M -65.5 M -36.7 M -38.1 M -131 M -29.6 M -75.4 M -74.6 M -107 M -107 M -34.4 M -32.9 M -

Long Term Debt

203 M 151 M 49.8 M 26.7 M 32.3 M 50.8 M 48.8 M 49.2 M - - - - - - -

Long Term Debt Current

1.48 M 1.56 M 4.44 M 3.89 M 3.49 M 2.12 M 2.61 M - - - - - - - -

Total Non Current Liabilities

246 M 185 M 80.4 M 26.1 M 14.5 M 47 M 50.9 M 49.8 M 720 K 779 K 322 K 31.2 M 33.1 M 22.3 M -

Total Current Liabilities

88.6 M 77.8 M 50.4 M 65.6 M 52.8 M 28.4 M 22.2 M 17.7 M 17.9 M 19.2 M 7.72 M 21.5 M - - -

Total Liabilities

335 M 262 M 131 M 91.7 M 67.3 M 75.4 M 73.1 M 67.5 M 18.6 M 20 M 8.04 M 52.7 M 50.2 M 39.1 M -

Deferred Revenue

1.21 M 10.7 M 7.18 M 4.21 M - 4.18 M 4.54 M 1 M - - - 16 M 13.8 M 13.6 M -

Retained Earnings

-947 M -885 M -846 M -780 M -713 M -555 M -460 M -366 M -278 M -214 M -101 M -71.9 M -68.7 M -62.1 M -

Total Assets

502 M 436 M 298 M 190 M 150 M 202 M 260 M 183 M 158 M 213 M 117 M 113 M 42.9 M 37.9 M -

Cash and Cash Equivalents

68 M 64.9 M 21.5 M 96.1 M 72.4 M 91 M 181 M 78.8 M 75.4 M 74.6 M 107 M 107 M 34.4 M 32.9 M -

Book Value

167 M 173 M 167 M 98.3 M 82.6 M 126 M 187 M 116 M 139 M 193 M 109 M 60.7 M -7.32 M -1.24 M -

Total Shareholders Equity

167 M 173 M 167 M 98.3 M 82.6 M 126 M 187 M 116 M 139 M 193 M 109 M 60.7 M -63.5 M -57.4 M -

All numbers in USD currency

Quarterly Balance Sheet Ardelyx

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

2.4 M 2.82 M 3.24 M 3.64 M 4.04 M 4.02 M 2.5 M 1.02 M 1.22 M 1.1 M 778 K 1.72 M 2.89 M 3.75 M 4.81 M 5.86 M 6.88 M 7.86 M 8.81 M 9.75 M 10.7 M 11.5 M 397 K 413 K 50.7 M 608 K 1.36 M 2.08 M 2.77 M 3.43 M 4.07 M 52 M 52 M 52 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

296 M 295 M 246 M 246 M 249 M 246 M 189 M 185 M 139 M 134 M 135 M 80.4 M 54.7 M 26.4 M 28.5 M 26.1 M 25.9 M 29.9 M 17.4 M 14.5 M 20.6 M 29.6 M 37.7 M 47 M 50.7 M 37.3 M 44.1 M 50.9 M 52.6 M 53 M 53.5 M 582 K 49.7 M 49.5 M 699 K 720 K 741 K 756 K - 779 K 789 K 713 K 292 K 322 K - 382 K - 31.2 M 35 M 33.3 M - - - - - - - - - - - - -

Total Liabilities

423 M 427 M 356 M 335 M 332 M 327 M 265 M 262 M 210 M 196 M 191 M 131 M 98.2 M 88 M 91.6 M 91.7 M 77.8 M 78.6 M 65.2 M 67.3 M 89.4 M 87.4 M 79.5 M 75.4 M 67.2 M 71 M 67.6 M 73.1 M 70.3 M 69.4 M 74.3 M 67.5 M 65.2 M 65.1 M 13.9 M 18.6 M 16.5 M 19.1 M 18.6 M 20 M 18.4 M 14.8 M 12.8 M 8.04 M 8.04 M 5.93 M 8.04 M 52.7 M 54.4 M 60.6 M 52.7 M 50.2 M 50.2 M 50.2 M - - - - - - - - -

Deferred Revenue

5.5 M 6.74 M 3.25 M 1.21 M 6.58 M 6.28 M 10.9 M 10.7 M 7.27 M 10.8 M 6.59 M 7.18 M 4.07 M 5.96 M 5.54 M 4.21 M 4 M - - - 527 K 1.41 M 2.72 M 4.18 M 4.18 M 4.18 M 4.18 M - - - - 1 M 1 M 1 M 1 M - - - - - - - - - - - 16 M 16 M 16.5 M 23.2 M 16 M 13.8 M 13.8 M 13.8 M - - - - - - - - -

Retained Earnings

-1 B -1 B -985 M -947 M -947 M -946 M -926 M -885 M -890 M -889 M -873 M -846 M -817 M -824 M -807 M -780 M -791 M -768 M -741 M -713 M -677 M -633 M -588 M -555 M -526 M -508 M -483 M -460 M -441 M -417 M -392 M -366 M -338 M -314 M -291 M -278 M -288 M -268 M -278 M -214 M -183 M -154 M -125 M -101 M -101 M -66.4 M -101 M -71.9 M -67.9 M -68 M -71.9 M -68.7 M -68.7 M -68.7 M - - - - - - - - -

Total Assets

588 M 576 M 505 M 502 M 486 M 467 M 410 M 436 M 368 M 343 M 342 M 298 M 289 M 211 M 217 M 190 M 145 M 132 M 129 M 150 M 171 M 205 M 210 M 202 M 199 M 217 M 235 M 260 M 119 M 138 M 166 M 183 M 207 M 229 M 143 M 158 M 143 M 164 M 158 M 213 M 241 M 155 M 180 M 117 M 117 M 148 M 117 M 113 M 118 M 123 M 113 M 42.9 M 42.9 M 42.9 M - - - - - - - - -

Cash and Cash Equivalents

46.3 M 97.2 M 31.2 M 68 M 42.7 M 90 M 30.8 M 64.9 M 47.4 M 41.9 M 36.1 M 21.5 M 33.8 M 30.1 M 92.5 M 96.1 M 61.6 M 53.4 M 47.1 M 72.4 M 75.3 M 86.7 M 84.1 M 91 M 91 M 100 M 106 M 181 M 92.7 M 89.6 M 92 M 78.8 M 75 M 91.8 M 67.7 M 75.4 M 59.5 M 63.6 M 75.4 M 24 M 160 M 147 M 172 M 107 M 107 M 142 M 107 M 107 M 112 M 118 M 107 M 34.4 M 34.4 M 34.4 M - 32.9 M - - - 10.8 M - - -

Book Value

164 M 149 M 149 M 167 M 154 M 140 M 146 M 173 M 158 M 147 M 151 M 167 M 191 M 123 M 125 M 98.3 M 66.9 M 53 M 64.2 M 82.6 M 81.4 M 118 M 131 M 126 M 131 M 146 M 168 M 187 M 49.2 M 68.6 M 91.8 M 116 M 141 M 163 M 129 M 139 M 127 M 145 M 139 M 193 M 223 M 141 M 168 M 109 M 109 M 142 M 109 M 60.7 M 63.3 M 62.9 M 60.7 M -7.32 M -7.32 M -7.32 M - - - - - - - - -

Total Shareholders Equity

164 M 149 M 149 M 167 M 154 M 140 M 146 M 173 M 158 M 147 M 151 M 167 M 191 M 123 M 125 M 98.3 M 66.9 M 53 M 64.2 M 82.6 M 81.4 M 118 M 131 M 126 M 131 M 146 M 168 M 187 M 49.2 M 68.6 M 91.8 M 116 M 141 M 163 M 129 M 139 M 127 M 145 M 139 M 193 M 223 M 141 M 168 M 109 M 109 M 142 M 109 M 60.7 M 63.3 M 62.9 M 60.7 M -63.5 M -63.5 M -63.5 M - -57.4 M - - - -48.3 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Ardelyx, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.74 0.63 % $ 5.94 B spainSpain
Incyte Corporation Incyte Corporation
INCY
$ 120.28 -1.32 % $ 23.5 B usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.32 -4.92 % $ 234 M schweizSchweiz
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 0.64 0.53 % $ 38.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Precision BioSciences Precision BioSciences
DTIL
$ 9.47 -2.17 % $ 121 M usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.14 -11.15 % $ 227 K usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 256.21 -1.4 % $ 15.5 B danmarkDanmark
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 71.31 5.19 % $ 1.43 B usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.56 1.3 % $ 48.7 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.31 -0.76 % $ 349 M britainBritain
Monopar Therapeutics Monopar Therapeutics
MNPR
$ 71.42 -3.16 % $ 529 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 78.67 0.95 % $ 15.1 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.53 -1.38 % $ 1.58 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.68 -2.39 % $ 255 M britainBritain
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.64 -21.66 % $ 75 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 27.45 4.77 % $ 3.49 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.12 -0.45 % $ 112 M franceFrance
BeyondSpring BeyondSpring
BYSI
$ 0.6 -2.21 % $ 24.7 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 46.48 0.67 % $ 7.66 B irlandaIrlanda
Altimmune Altimmune
ALT
$ 1.94 -8.51 % $ 171 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.79 -0.77 % $ 52.8 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.5 -5.43 % $ 5.53 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 9.41 -0.84 % $ 258 M israelIsrael
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 49.04 -0.41 % $ 6.56 B usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 8.18 -0.73 % $ 103 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.3 -1.93 % $ 2.19 B canadaCanada
Cullinan Management Cullinan Management
CGEM
$ 11.34 -3.32 % $ 683 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 87.2 -0.36 % $ 21.1 B germanyGermany
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.47 -0.97 % $ 775 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 3.95 12.07 % $ 52.6 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.21 -11.68 % $ 55.3 M israelIsrael
AnaptysBio AnaptysBio
ANAB
$ 48.4 0.9 % $ 1.4 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 21.33 -2.11 % $ 239 M usaUSA
Adagene Adagene
ADAG
$ 2.02 -4.95 % $ 119 M chinaChina
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.31 -5.67 % $ 433 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 19.85 -2.36 % $ 3.43 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.75 0.09 % $ 4.88 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 10.4 1.76 % $ 93.9 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.5 -9.09 % $ 222 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 31.77 1.23 % $ 1.84 B usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 18.89 -6.21 % $ 1.79 B usaUSA
Equillium Equillium
EQ
$ 1.45 -3.33 % $ 83.1 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.6 -14.05 % $ 91 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 2.46 -3.35 % $ 130 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 18.13 9.85 % $ 3.05 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 2.21 3.76 % $ 19 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.51 -9.88 % $ 192 M schweizSchweiz